762286-17-9

Upstream product

• 4255-62-3 4,4-dimethylcyclohexane-1-one 
• 762286-16-8 ((S)-1-{[(S)-1-(4,4-Dimethyl-cyclohexyl)-pyrrolidin-3-yl]-methyl-carbamoyl}-pyrrolidin-3-yl)-methyl-carbamic acid tert-butyl ester 
• 762285-86-9 {(S)-1-[((S)-1-Benzyl-pyrrolidin-3-yl)-methyl-carbamoyl]-pyrrolidin-3-yl}-methyl-carbamic acid tert-butyl ester 
• 762285-87-0 Methyl-[(S)-1-((S)-methyl-pyrrolidin-3-yl-carbamoyl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester 
• 169749-99-9 (3S)-(-)-1-benzyl-3-(methylamino)pyrrolidine 

Relevant academic research and scientific papers

Bis(aminopyrrolidine)-derived ureas (APUs) as potent MCH1 receptor antagonists

Ureas derived from two substituted 3-aminopyrrolidine subunits were prepared as constrained analogs of a linear lead compound and tested as antagonists of the MCH1 receptor. The series was optimized for substitution and stereochemistry to generate a functional antagonist with a Ki of 3.3 nM and IC50 of 12 nM (GTPγS).

MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO

Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure: including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, X, R1, R2, R3, R4, and R5 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.